Factor VIII genotype and the risk of developing highresponding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children

Nadine G Andersson; Veerle Labarque; Mutlu Kartal-Kaess; Fernando Pinto; Torben Stamm Mikkelsen; Rolf Ljung; PedNet Study Group

doi:10.3324/haematol.2023.284095

Factor VIII genotype and the risk of developing highresponding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children

Haematologica. 2024 Apr 1;109(4):1293-1296. doi: 10.3324/haematol.2023.284095.

Authors

Nadine G Andersson¹, Veerle Labarque², Mutlu Kartal-Kaess³, Fernando Pinto⁴, Torben Stamm Mikkelsen⁵, Rolf Ljung⁶, PedNet Study Group⁷

Affiliations

¹ Center for Thrombosis and Hemostasis, Skåne University Hospital, Malmö, Sweden; Department of Pediatrics, Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences and Pediatrics, Lund University, Lund. nadine.gretenkort_andersson@med.lu.se.
² Department of Pediatrics, Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium.
³ Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, University Hospital, University of Bern, Bern.
⁴ Royal Hospital for Children, Glasgow, UK.
⁵ Department of Pediatric Oncology and Hematology, University Hospital, Aarhus, Denmark.
⁶ Department of Pediatrics, Skåne University Hospital, Lund.
⁷ PedNet group, Table S1, Supplement.

No abstract available

MeSH terms

Child
Factor VIII / genetics
Genotype
Hemophilia A* / drug therapy
Hemophilia A* / genetics
Hemostatics*
Humans
Risk Factors

Substances

Factor VIII
Hemostatics

Grants and funding

Funding: This study is supported by the PedNet Hemophilia Research Foundation, by grants from Region Skåne (2022-1195) and Aroseniusfonden, Sweden (2022). Unrestricted sponsorship for the PedNet Haemophilia Foundation is currently received from Bayer AG, Biotest AG, LFB Biotechnologies, Novo Nordisk Healthcare AG, Pfizer SRL, CSL Behring GmbH, Sanofi, Swedish Orphan Biovitrum AB (SOBI), Takeda and Hoffmann La-Roche.